Literature DB >> 6812166

Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity.

M Livio, A Del Maschio, C Cerletti, G de Gaetano.   

Abstract

Aspirin and indomethacin do interact with the same site on cyclo-oxygenase. This suggestion is based on in vitro studies on ram seminal vesicles and in vivo drug interaction studies on rat platelets. The purpose of the present study was to ascertain whether the same interaction also occurred after administration of both drugs to human volunteers. Platelet aggregation induced by sodium arachidonate or by collagen, and formation of platelet MDA and TxB2 were measured before, two and 48 hours after ingestion of either indomethacin (50 mg) or aspirin (500 mg) or of both drugs (30 minutes apart). While the inhibitory effect of indomethacin on these parameters was short lasting, that of aspirin persisted for at least 48 hours. However, when both drugs were given concurrently, the long-lasting effect of aspirin was no longer detectable. Since competition at levels other than platelets was unlikely, this study indicates that indomethacin and aspirin inhibit human platelet cyclo-oxygenase by the same basic mechanism. Acetylation of the enzyme appears to be a secondary mechanism which makes the inhibitory effect of aspirin persistent.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6812166     DOI: 10.1016/0090-6980(82)90123-x

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  7 in total

1.  A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.

Authors:  M Ouellet; D Riendeau; M D Percival
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers.

Authors:  D J W van Kraaij; A H I Hovestad-Witterland; M de Metz; E J Vollaard
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

3.  Confirmation of reported aspirin use in community studies: utility of serum thromboxane B2 measurement.

Authors:  Nicole Dodge Zantek; Russell V Luepker; Sue Duval; Karen Miller; Niki Oldenburg; Alan T Hirsch
Journal:  Clin Appl Thromb Hemost       Date:  2013-05-07       Impact factor: 2.389

4.  Relationship between platelet cyclooxygenase pathway and plasma malondialdehyde-like material.

Authors:  F Violi; A Ghiselli; C Alessandri; L Iuliano; C Cordova; F Balsano
Journal:  Lipids       Date:  1985-05       Impact factor: 1.880

5.  Interactions of inhibitors of the lipoxygenase and cyclooxygenase pathways with a supplementary binding site on soybean lipoxygenase.

Authors:  I Baumann; J Baumann; G Wurm
Journal:  Br J Pharmacol       Date:  1984-12       Impact factor: 8.739

6.  Antagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterol-fed rabbit.

Authors:  G Kaber; B Kaiser; D Baumgärtel-Allekotte; Bh Rauch; S Nossmann; Kh Heim; Aa Weber; N Nagy; Jw Fischer; K Schrör
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 7.  Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis.

Authors:  Tobias Kurth; Charles H Hennekens; Julie E Buring; J Michael Gaziano
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.